首页> 外文期刊>The lancet oncology >The use of opioids and sedatives at the end of life.
【24h】

The use of opioids and sedatives at the end of life.

机译:在寿命终止时使用阿片类药物和镇静剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Opioids and sedative drugs are commonly used to control symptoms in patients with advanced cancer. However, it is often assumed that the use of these drugs inevitably results in shortening of life. Ethically, this outcome is excused by reference to the doctrine of double effect. In this review, we assess the evidence for patterns of use of opioids and sedatives in palliative care and examine whether the doctrine of double effect is needed to justify their use. We conclude that patients are more likely to receive higher doses of both opioids and sedatives as they get closer to death. However, there is no evidence that initiation of treatment, or increases in dose of opioids or sedatives, is associated with precipitation of death. Thus, we conclude that the doctrine of double effect is not essential for justification of the use of these drugs, and may act as a deterrent to the provision of good symptom control.
机译:阿片类药物和镇静药通常用于控制晚期癌症患者的症状。但是,通常认为使用这些药物不可避免地会缩短寿命。从伦理上讲,这种结果可以通过引用双重效应学说得到原谅。在这篇综述中,我们评估了在姑息治疗中使用阿片类药物和镇静剂的模式的证据,并检查了是否需要双重效应学说来证明其合理使用。我们得出的结论是,随着患者接近死亡,他们更有可能接受更高剂量的阿片类药物和镇静剂。但是,没有证据表明开始治疗或阿片类药物或镇静剂剂量增加与死亡人数有关。因此,我们得出结论,双重作用学说对于使用这些药物的合理性不是必不可少的,并且可以起到抑制良好症状控制的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号